State of the Art on T-cell lymphomas: the Epidemiology
R. Liang
State of the Art on T-cell lymphomas: the Pathogenesis
E.S. Jaffe
Conventional treatment of peripheral T-cell lymphomas: view from GELA and European perspective
C. Gisselbrecht
Management of patients with peripheral T-cell lymphoma
J.O. Armitage
Conventional treatment of peripheral T-cell lymphomas: the Asian
perspective
K. Tobinai
T-cell lymphoma. Standard treatment. The Mexican experience
A. Avilès
Nodal peripheral T-cell lymphomas correspond to distinct mature T-cell
populations
T. Rüdiger
Gene expression analysis of peripheral T-cell lymphoma not otherwise specified reveals two distinct subgroups and recurrent pdgfra deregulation
S.A. Pileri, P.P. Piccaluga, C. Agostinelli, S. Zupo, A. Carbone, F. Facchetti, B. Falini,
M. Ferrarini, A. Gallamini, D. Novero, M. Paulli, P. L. Zinzani, R. Dalla Favera
Phase II trial of romidepsin (FK228 or depsipeptide) in peripheral T-cell lymphoma: clinical activity and molecular markers
R.L. Piekarz, R. Frye, M. Turner, J. Wright, S. Allen, M.H. Kirschbaum, J. Zain, M. Prince, L. Hutchins, L.C. Showe, W.D. Figg, T. Fojo, S.E. Bates
Current status of anti-CD30 monoclonal antibody therapy in anaplastic
lymphoma and Hodgkin’s lymphoma
S.J. Proctor, J. Wilkinson
Forodesine – Preclinical studies
V. Gandhi
Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma
C. Querfeld, T.M. Kuzel, J. Guitart, S.T. Rosen
Nelarabine: a new age in the management of lymphoid malignancies
M.J. Keating
New drugs for peripheral T-cell lymphomas
B.D. Cheson
Cutaneous T-cell lymphomas: histology
M. Santucci
Molecular biology of cutaneous T-cell lymphomas
E. Berti, S. Gimelli, L. Venegoni, V. Merlo, R. Riboni, O. Zuffardi, M. Paulli
Alemtuzumab (Campath-1H)
C. Querfeld, T.M. Kuzel, J. Guitart, S.T. Rosen
Optimizing denileukin diftitox (Ontak®) therapy
M. Duvic
Gemcitabine
M. Tani, E. Marchi, M. Fina, L. Alinari, V. Stefoni, P.L. Zinzani
Liposomal chemotherapy in cutaneous T-cell lymphomas: current status and future prospects
U. Wollina
Interferons in cutaneous T-cell lymphomas
R. Dummer, A. Cozzio, M. Urosevic
Optimizing bexarotene therapy for cutaneous T-cell lymphoma
M. Duvic
Bortezomib
P.L. Zinzani
Animal models of T-cell lymphomas
Y-W. Lin, P.D. Aplan
Rationale for the design of combination therapies that are active in T-cell lymphomas?
W. Plunkett
Peripheral T-cell lymphoma: prognostic factors
D.D. Weisenburger
Prognostic factors in cutaneous T-cell lymphoma
R. Willemze
Chemotherapy for peripheral T-cell lymphoma
J.M. Vose
Chemotherapy in cutaneous T-cell lymphoma
S. Rupoli, M.G. Bernengo, R. Alterini, M. Cantonetti, P.L. Zinzani, N. Pimpinelli
Autotransplant in peripheral T-cell lymphomas
P. Reimer
Relapsed peripheral T-cell non-Hodgkin’s lymphomas: outcome
following reduced-intensity conditioning allogeneic stem cell transplantation
P. Corradini, A. Dodero, L. Farina, M. Casini, F. Narni, F. Patriarca, F. Benedetti, A. Rambaldi, E. Angelucci, A.M. Gianni, C. Tarella
Auto and allotransplant in cutaneous T-cell lymphomas
F. Onida